Brent Neuschwander-Tetri

Professor of Internal Medicine

Saint Louis University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

INTRODUCTION: Risk of cardiovascular (CV) events is estimated by the Framingham Risk Score (FRS), Pooled Cohort Equation (PCE), and the American Heart Association Predicting Risk of cardiovascular disease (CVD) EVENTs (PREVENT) equation. The applicability of these risk tools in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) is uncertain. This study sought to determine the accuracy of the FRS, PCE, and PREVENT in a real-world cohort of patients with MASLD. METHODS: This analysis included US adults 30 years and older with MASLD in the TARGET-NASH study. Five to ten-year CV risk was estimated using original and recalibrated versions of the FRS and PCE, and original PREVENT equation. Discrimination among prediction models was assessed using the Harrell concordance statistic, and calibration was evaluated using a modified Hosmer Lemeshow test comparing observed and predicted CV events. Logistic regression was used to assess the contribution of liver disease to observed CV events. RESULTS: Overall, 1,090 patients were included. There was an increase in observed CV events from metabolic dysfunction-associated steatotic livers to cirrhosis. FRS demonstrated a weak ability to identify patients who went on to experience a CV event (C-statistic 0.58, 95% confidence interval 0.52–0.63) as did the American Heart Association PREVENT model (C-statistic 0.60, 95% confidence interval 0.54–0.65). Both the FRS and PCE demonstrated a significant lack of calibration ( P < 0.01), with overestimation in the highest deciles and underestimation in the lowest deciles of predicted risk. DISCUSSION: Commonly used tools to identify CV risk performed poorly in a cohort of patients with MASLD. Because CV related death is the greatest source of mortality among patients with MASLD, better risk assessment tools are required.

Year:

2026

INTRODUCTION: The effects of metabolic syndrome (MetS), its individual components, and baseline liver histology, on the rates of progression and regression of nonalcoholic fatty liver disease (NAFLD), were evaluated. METHODS: We conducted a post hoc analysis of a multicenter prospective cohort study using the noninterventional registry of the Nonalcoholic Steatohepatitis Clinical Research Network (2002–2022). We included patients aged 18 years or older with biopsy-proven NAFLD. Outcomes included progression/regression of histology defined by changes in NAFLD Activity Score, nonalcoholic steatohepatitis, or fibrosis. Crude incidence rates were compared among patients with MetS vs those without using Kaplan-Meier curves and log-rank test. Cox proportional hazard models were used to estimate effects of MetS and its components on the fibrosis progression/regression. RESULTS: We included 452 patients; the mean age was 51 years, one-third was male, and 85% was White. The median follow-up was 4.3 (range: 1–15.6) years. At baseline, patients with MetS, large waist circumference, and impaired glucose tolerance/diabetes had worse ballooning and fibrosis scores and a higher prevalence of definite nonalcoholic steatohepatitis than those without. MetS was not associated with fibrosis progression or regression. Impaired glucose tolerance/diabetes was associated with a higher risk of fibrosis progression (adjusted hazard ratio = 1.61; 95% confidence interval: 1.11–2.34) whereas hypertension was associated with a lower risk (adjusted hazard ratio = 0.64; 95% confidence interval: 0.43–0.96). DISCUSSION: In the cohort of patients with NAFLD, MetS was associated with greater histological severity at baseline but was not a risk factor of disease progression or regression. Impaired glucose/diabetes was associated with a higher rate and hypertension with a lower rate of fibrosis progression.

Year:

2026

Background Polypharmacy is common among patients with multiple comorbidities but may compromise patient health due to medication interactions, cumulative side effects and compliance challenges. Aim Characterise the extent of polypharmacy and assess the effects of sex, liver disease severity and comorbidities in patients with metabolic dysfunction associated steatotic liver disease (MASLD) in a real‐world setting. Methods Data from adults enrolled in TARGET‐NASH, a real‐world longitudinal observational cohort of patients with MASLD, were utilised. Reported medications were counted and relationships to disease severity, sex and insurance are described. Significant differences were identified using Chi‐square or Fisher's exact test. Results Medication use was evaluated in 5190 adults (59% female) in the United States with the full spectrum of MASLD revealing that 90% were prescribed five or more medications and 75% were prescribed ten or more medications (63% of whom were females). Patients with cirrhosis were often prescribed nonsteroidal anti‐inflammatory drugs (64%), opioids (55%), or benzodiazepines (45%). Females were prescribed more medications than males, particularly selective serotonin reuptake inhibitors (37% vs. 20%), opioids (44% vs. 37%), proton pump inhibitors (63% vs. 52%) and benzodiazepines (41% vs. 31%). Conclusions Polypharmacy is common among patients with MASLD. Those with cirrhosis are most affected, and women with cirrhosis are at an even greater risk. Opioid, benzodiazepine, and nonsteroidal anti‐inflammatory drug use is prevalent among patients with cirrhosis despite the known associated risks. Frequent medication use for chronic pain in patients with cirrhosis highlights the need for management plans that optimise safety balanced against therapeutic efficacy.

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (19)

Anutosh Chakraborty

Professor

University of Florida

UNITED STATES
View details

Matthew Dukewich

University of Southern California

UNITED STATES
View details

Arun Sanyal

Professor of Medicine

Virginia Commonwealth University

UNITED STATES
View details

Jeffrey B. Schwimmer

University of California San Diego School of Medicine

UNITED STATES
View details

Matthew Ryan Smith

Assistant Professor of Medicine

Emory University

UNITED STATES
View details

Diana Barb

Associate Professor

University of Florida

UNITED STATES
View details

David Kleiner

National Cancer Institute

UNITED STATES
View details

Michelle T. Long

Boston University School of Medicine

UNITED STATES
View details

Raj Vuppalanchi

Professor of Medicine

Indiana University School of Medicine

UNITED STATES
View details

Francis Pike

Associate Professor

Indiana University-Purdue University Indianapolis

UNITED STATES
View details

Joel Lavine

Professor with tenure

Columbia University

UNITED STATES
View details

Manal Abdelmalek

Professor of Medicine, Director MASLD Clinical Research

Mayo Clinic

UNITED STATES
View details

Srinivasan Dasarathy

Professor of Medicine

Cleveland Clinic

UNITED STATES
View details

Zachery Jarrell

Assistant Professor

Emory University

UNITED STATES
View details

Norah A. Terrault

Professor of Medicine

University of Southern California Keck School of Medicine

UNITED STATES
View details

Bilal Hameed

Professor of Medicine

University of California, San Francisco

UNITED STATES
View details

Jennifer Dodge

Associate Professor

University of Southern California

UNITED STATES
View details

Wendy Mack

Professor of Population and Public Health Sciences

University of Southern California

UNITED STATES
View details

Mary E. Rinella

Professor of Medicine

University of Chicago Pritzker School of Medicine

UNITED STATES
View details